| 词条 | Abciximab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 477237058 | type = mab | mab_type = Fab | source = xi/o | target = CD41 7E3 | tradename = Reopro | Drugs.com = {{drugs.com|monograph|abciximab}} | pregnancy_category = C (US) | legal_UK = POM | routes_of_administration = IV | bioavailability = | protein_bound = | metabolism = | elimination_half-life = <10 min–30 min | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 143653-53-6 | ATC_prefix = B01 | ATC_suffix = AC13 | ATC_supplemental = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00054 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = X85G7936GV | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D02778 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1201584 | C=2101 | H=3229 | N=551 | O=673 | S=15 | molecular_weight = 47455.4 g/mol }}Abciximab or Abcixifiban[1] (previously known as c7E3 Fab), a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[2] While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.[3] Indications for useAbciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure[4] and a decreased need for repeated coronary artery revascularization in the first month following the procedure.[5] Research also shows that this drug can be of use for patients with diabetes and chronic renal insufficiency. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize. PharmacokineticsAbciximab has a plasma half-life of about ten minutes, with a second phase half-life of about 30 minutes. However, its effects on platelet function can be seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated. Abciximab does not require dose adjustments for patients with renal failure.[6] Side-effectsMany of the side effects of abciximab are due to its anti-platelet effects. This includes an increased risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal hemorrhage. Thrombocytopenia is a rare but known serious risk characterized by a severe drop in platelets circulating in the blood. Abciximab induced thrombocytopenia is usually rapid occurring hours after administration but may occur up to 16 days later.[7] Transfusing platelets is the only known treatment for abciximab-induced thrombocytopenia, but this therapy may have limited effectiveness because the drug may bind and inhibit the receptors on the newly transfused platelets. References1. ^https://www.academia.edu/31375132/COMPREHENSIVE_MEDICAL_REFERENCE_and_REVIEW_FOR_MCCQE_AND_USMLE_II 2. ^{{cite web|url=https://www.drugs.com/cdi/abciximab.html|title=Abciximab|work=Drugs.com|accessdate=13 March 2010| archiveurl= https://web.archive.org/web/20100420014357/http://www.drugs.com/cdi/abciximab.html| archivedate= 20 April 2010 | deadurl= no}} 3. ^{{cite journal|url=http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list70.pdf|journal=WHO Drug Information|volume=7|issue=4|title=International Nonproprietary Names for Pharmaceutical Substances|year=1993}} 4. ^{{cite journal | title = Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. | journal = The New England Journal of Medicine | volume = 330 | issue = 14 | pages = 956–61 | year = 1994 | pmid = 8121459 | doi = 10.1056/NEJM199404073301402 }} 5. ^{{Cite journal | last1 = Tcheng | first1 = J. E. | last2 = Kandzari | first2 = D. E. | last3 = Grines | first3 = C. L. | last4 = Cox | first4 = D. A. | last5 = Effron | first5 = M. B. | last6 = Garcia | first6 = E. | last7 = Griffin | first7 = J. J. | last8 = Guagliumi | first8 = G. | last9 = Stuckey | first9 = T. | last10 = Turco | first10 = M. | last11 = Fahy | first11 = M. | last12 = Lansky | first12 = A. J. | last13 = Mehran | first13 = R. | last14 = Stone | first14 = G. W. | last15 = Cadillac | first15 = I. | doi = 10.1161/01.CIR.0000087601.45803.86 | title = Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial | journal = Circulation | volume = 108 | issue = 11 | pages = 1316–1323 | year = 2003 | pmid = 12939213| pmc = }} 6. ^Usta C, Turgut NT, Bedel A (2016) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=27519521 How abciximab might be clinically useful.] Int J Cardiol {{DOI|10.1016/j.ijcard.2016.07.213}} {{PMID|27519521}} 7. ^Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration. Platelets. 2011;22(4):302-4. {{doi|10.3109/09537104.2010.518324}}. External links
4 : GpIIb/IIIa inhibitors|Monoclonal antibodies|Janssen Biotech|Eli Lilly and Company |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。